Home › Funds › Nantahala Capital Management, LLC › RARE
Nantahala Capital Management, LLC position in RARE
ULTRAGENYX PHARMACEUTICAL IN · Health Care
Nantahala Capital Management, LLC reported holding 2,339,293 shares of RARE (ULTRAGENYX PHARMACEUTICAL IN) in its Q3 2026 13F filing — a position valued at US$35.2M, representing 1.61% of its reported portfolio and ranking #15 among its reported holdings. Nantahala Capital Management, LLC first reported this position in Q3 2026.
Last updated: 2026-11-14 · Source: SEC EDGAR Form 13F-HR
How Nantahala Capital Management, LLC's RARE position evolved
Nantahala Capital Management, LLC first disclosed a stake in RARE in Q3 2026 at 2,339,293 shares (US$35.2M).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2026 | 2.34M | $35.16M | New |
About RARE and 13F data
RARE (ULTRAGENYX PHARMACEUTICAL IN) is a Health Care company. 23 other funds we track also report a position in RARE — the largest reported positions include RTW INVESTMENTS, LP (US$260.3M), FRONTIER CAPITAL MANAGEMENT CO LLC (US$95.1M), Bellevue Group AG (US$66.2M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding RARE
- RTW INVESTMENTS, LP 7.80M sh · $260.34M · Q2 2026
- FRONTIER CAPITAL MANAGEMENT CO LLC 2.85M sh · $95.09M · Q2 2026
- Bellevue Group AG 1.98M sh · $66.20M · Q2 2026
- MPM BioImpact LLC 1.42M sh · $47.35M · Q2 2026
More on Nantahala Capital Management, LLC
FAQ
How long has Nantahala Capital Management, LLC held RARE?
Nantahala Capital Management, LLC has disclosed RARE holdings in 1 of the last 1 reported quarters, going back to Q3 2026.
What is Nantahala Capital Management, LLC's current position in RARE?
As of Q3 2026, Nantahala Capital Management, LLC holds 2.34M shares of RARE (ULTRAGENYX PHARMACEUTICAL IN), valued at $35.16M, representing 1.61% of its reported portfolio and ranking #15.
Has Nantahala Capital Management, LLC been buying or selling RARE?
In the latest 13F filing (Q3 2026), Nantahala Capital Management, LLC newly opened its position in RARE.
Which other funds hold RARE?
Other major institutional holders of RARE include RTW INVESTMENTS, LP, FRONTIER CAPITAL MANAGEMENT CO LLC, Bellevue Group AG, among 23 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.